Neurocrine Biosciences Inc. (NBIX)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
49.54+0.60 (+1.23%)
At close: 4:00 PM EDT
People also watch:
ALKSLGNDPGNXNKTRINCY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open49.27
Prev Close48.94
Bid40.12 x 100
Ask60.00 x 1000
Day's Range48.83 - 50.11
52wk Range31.25 - 58.46
1y Target EstN/A
Market Cap4.3B
P/E Ratio (ttm)-34.69
Beta0.04
Volume505,015
Avg Vol (3m)1,014,720
Dividend & Yield0.00 (0.00%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Capital Cube16 days ago

    ETF’s with exposure to Neurocrine Biosciences, Inc. : August 12, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to Neurocrine Biosciences, Inc. Here are 5 ETF’s with the largest exposure to NBIX-US. Comparing the performance and risk of Neurocrine Biosciences, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : NBIX-US : August 11, 2016
    Capital Cube18 days ago

    Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : NBIX-US : August 11, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Neurocrine Biosciences, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving ... Read more (Read more...)

  • NBIX: NDA for Valbenazine in Tardive Dyskinesia Set to be Filed; Data From Tourette Syndrome Trials at Year End
    Zacks Small Cap Research24 days ago

    NBIX: NDA for Valbenazine in Tardive Dyskinesia Set to be Filed; Data From Tourette Syndrome Trials at Year End

    Neurocrine is currently developing valbenazine as a treatment in both tardive dyskinesia (TD) and Tourette syndrome (TS). The Kinect-3 study was a randomized, parallel group, double blind, placebo controlled Phase 3 clinical trial testing valbenazine in moderate to severe TD patients with underlying schizophrenia, schizoaffective disorder, or mood disorder. A total of 234 patients were randomized to receive placebo, 40 mg of valbenazine, or 80 mg of valbenazine once daily for six weeks.